Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy

Patients with glucocorticoid-dependent Duchenne muscular dystrophy (DMD) have increased fracture risk and reduced bone mineral density (BMD), often precipitating mobility loss.

Citation:
Zacharin M, Lim A, Gryllakis J, Siafarikas A, Jefferies C, Briody J, et al. Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy. J Clin Endocrinol Metab. 2021;106(8):2328-42.

Keywords:
Bisphosphonate; bone density; Duchenne; glucocorticoid; zoledronic acid

Abstract:
Patients with glucocorticoid-dependent Duchenne muscular dystrophy (DMD) have increased fracture risk and reduced bone mineral density (BMD), often precipitating mobility loss.